Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients ...

ORIC Pharmaceuticals (ORIC) announced that the company has entered into a supply agreement with Janssen Research & ...

Mark Zuckerberg’s unexpected ‘free speech’ overhaul of Meta’s content moderation has sparked concerns among advertisers that ...

By scrapping its fact-checking programme and relaxing hate speech rules, Meta risks losing the trust of brands, which ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “outperform” rating reiterated by Wedbush in a research ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...